By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopolitikOne-OffGesundheit & Medizin3J
Manifold MarketsKein KYCVerifizierte AuflösungsdatenOrdentlich kalibriertWarnung zur DatenqualitätQuelldaten beeinträchtigt
Daten vom 25.10.2026, 20:15 UTC · Richtlinie pm-quality-4
Aktuelle Community-PrognoseJa 53.5%
Prognostiker
5
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 3 Stunden
Veraltet18. Nov. 22, 02:41 UTC1. Jan. 30, 08:00 UTC
Trends
Regeln
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
